SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec zooms on collaborating with Refana for Covid-19 vaccine

11 Jun 2020 Evaluate

Panacea Biotec is currently trading at Rs. 241.95, up by 39.15 points or 19.30% from its previous closing of Rs. 202.80 on the BSE.

The scrip opened at Rs. 229.95 and has touched a high and low of Rs. 243.35 and Rs. 220.20 respectively. So far 241355 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 243.35 on 11-Jun-2020 and a 52 week low of Rs. 90.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 243.35 and Rs. 153.30 respectively. The current market cap of the company is Rs. 1486.86 crore.

The promoters holding in the company stood at 73.59%, while Institutions and Non-Institutions held 1.76% and 24.65% respectively.

Panacea Biotec has collaborated with Refana Inc. USA to make Covid-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland. The collaboration aims to bring to patients a whole inactivated virus-based vaccine for Covid-19.

Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World. Both Panacea and Refana will undertake sales and distribution of the vaccine in their respective territories.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×